MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$32.246M
EPS
-$0.89
Unit: Million (M) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
0
0
-17*
10
Research and development
26.412
17.319
15*
19.639
General and administrative
8.483
6.635
9*
3.689
Total operating expenses
34.895
23.954
24*
23.328
Loss from operations
-34.895
-23.954
-41*
-13.328
Change in fair value of convertible preferred stock forward
-
-
9*
-
Interest income
2.651
2.284
1*
0.862
Other expense, net
0.002
0.004
0*
0.009
Total other income, net
2.649
2.28
10*
0.853
Net loss
-32.246
-21.674
-31
-12.475
Basic EPS
-0.89
-0.64
-2.931
-8.07
Diluted EPS
-0.89
-0.64
-2.931
-8.07
Basic Average Shares
36,135,644
33,670,148
10,728,262
1,545,010
Diluted Average Shares
36,135,644
33,670,148
10,728,262
1,545,010
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest income
$2.651M
Net loss
-$32.246M
Total other income,
net
$2.649M
Other expense, net
$0.002M
Loss from operations
-$34.895M
Total operating
expenses
$34.895M
Research and development
$26.412M
General and
administrative
$8.483M
Buy us a coffee
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)